BG102163A - Inhibitors of adenosinekinase modified in c-4'position - Google Patents

Inhibitors of adenosinekinase modified in c-4'position

Info

Publication number
BG102163A
BG102163A BG102163A BG10216398A BG102163A BG 102163 A BG102163 A BG 102163A BG 102163 A BG102163 A BG 102163A BG 10216398 A BG10216398 A BG 10216398A BG 102163 A BG102163 A BG 102163A
Authority
BG
Bulgaria
Prior art keywords
inhibitors
adenosinekinase
modified
diseases
relates
Prior art date
Application number
BG102163A
Other languages
Bulgarian (bg)
English (en)
Inventor
Serge Boyer
Mark Erion
Bheemarao Ugarkar
Original Assignee
Gensia Sicor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gensia Sicor filed Critical Gensia Sicor
Publication of BG102163A publication Critical patent/BG102163A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
BG102163A 1995-06-07 1998-01-07 Inhibitors of adenosinekinase modified in c-4'position BG102163A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/486,161 US5674998A (en) 1989-09-15 1995-06-07 C-4' modified adenosine kinase inhibitors
PCT/US1996/010404 WO1996040705A1 (en) 1995-06-07 1996-06-07 C-4' modified adenosine kinase inhibitors

Publications (1)

Publication Number Publication Date
BG102163A true BG102163A (en) 1998-10-30

Family

ID=23930844

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102163A BG102163A (en) 1995-06-07 1998-01-07 Inhibitors of adenosinekinase modified in c-4'position

Country Status (24)

Country Link
US (1) US5674998A (cs)
EP (1) EP0832091B1 (cs)
JP (1) JPH11507387A (cs)
KR (1) KR19990022740A (cs)
CN (1) CN1190401A (cs)
AP (1) AP9701165A0 (cs)
AT (1) ATE257841T1 (cs)
AU (1) AU6178396A (cs)
BG (1) BG102163A (cs)
BR (1) BR9609013A (cs)
CA (1) CA2220642A1 (cs)
CZ (1) CZ392797A3 (cs)
DE (1) DE69631330T2 (cs)
EA (1) EA199800009A1 (cs)
HU (1) HUP9802193A3 (cs)
IL (1) IL122335A0 (cs)
IS (1) IS4621A (cs)
MX (1) MX9709859A (cs)
NO (1) NO975585L (cs)
OA (1) OA10639A (cs)
PL (1) PL323904A1 (cs)
SK (1) SK166097A3 (cs)
TR (1) TR199701539T1 (cs)
WO (1) WO1996040705A1 (cs)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2109796T3 (es) * 1994-05-03 1998-01-16 Ciba Geigy Ag Derivados de pirrolopirimidilo con efecto antiproliferante.
US6140332A (en) * 1995-07-06 2000-10-31 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US6051578A (en) * 1996-02-12 2000-04-18 Pfizer Inc. Pyrazolopyrimidines for treatment of CNS disorders
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
YU25500A (sh) * 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
AU769578B2 (en) * 1999-08-27 2004-01-29 Icn Pharmaceuticals, Inc. Pyrrolo(2,3-d)pyrimidine nucleoside analogs
US6831069B2 (en) 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
ATE247657T1 (de) 1999-09-17 2003-09-15 Basf Ag Pyrazolopyrimidine als arzneimittel
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
JP2003516962A (ja) * 1999-12-16 2003-05-20 アルコン，インコーポレイテッド 視神経損傷および網膜損傷の処置のためのアデノシンキナーゼのインヒビター
KR100517163B1 (ko) * 2000-02-10 2005-09-26 미쯔이카가쿠 가부시기가이샤 1-인산화 당유도체 아노머의 선택적인 제조방법 및뉴클레오사이드의 제조방법
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US7414036B2 (en) * 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
AU2002951247A0 (en) * 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
BRPI0400869B8 (pt) * 2004-03-02 2021-05-25 Univ Estadual Campinas Unicamp novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases
JP2008520744A (ja) 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
DK1848718T3 (da) 2005-02-04 2012-08-27 Millennium Pharm Inc E1 aktiveringsenzymhæmmere
BRPI0615157A2 (pt) * 2005-08-12 2016-09-13 Merck & Co Inc composto, composição farmacêutica, métodos para inibir a replicação viral em um paciente humano, e para tratar uma infecção viral em um paciente humano, e, uso de um composto
KR101450535B1 (ko) 2006-02-02 2014-10-14 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｅ１ 활성화 효소의 억제제
AU2007233302C1 (en) 2006-04-04 2013-06-06 The Regents Of The University Of California Kinase antagonists
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009088986A1 (en) 2008-01-04 2009-07-16 Intellikine, Inc. Certain chemical entities, compositions and methods
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
EP2252293B1 (en) 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
JP5819195B2 (ja) 2008-10-16 2015-11-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 融合環ヘテロアリールキナーゼ阻害剤
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
CN102421780A (zh) 2009-05-14 2012-04-18 米伦纽姆医药公司 氨基磺酸((1s，2s，4r)-4-{4-[(1s)-2，3-二氢-1h-茚-1-基氨基]-7h-吡咯并[2，3-d]嘧啶-7-基}-2-羟基环戊基)甲酯盐酸盐
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
NZ612909A (en) 2011-01-10 2015-09-25 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
CN103491962B (zh) 2011-02-23 2016-10-12 因特利凯有限责任公司 激酶抑制剂的组合及其用途
JP6027611B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
WO2013032591A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AU2012341028C1 (en) 2011-09-02 2017-10-19 Mount Sinai School Of Medicine Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
EA035493B1 (ru) 2011-12-22 2020-06-25 Янссен Байофарма, Инк. Замещенные нуклеозиды, нуклеотиды и их аналоги
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
NZ702571A (en) 2012-06-29 2017-02-24 Pfizer 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
CA2886240A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
SMT201800561T1 (it) 2012-11-01 2018-11-09 Infinity Pharmaceuticals Inc Trattamento di cancri usando modulatori di isoforme di pi3 chinasi
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
JP6453322B2 (ja) 2013-06-26 2019-01-16 アリオス バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EA201690526A1 (ru) 2013-10-11 2017-02-28 Алиос Биофарма, Инк. Замещенные нуклеозиды, нуклеотиды и их аналоги
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
JP6701088B2 (ja) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
EP3212201B1 (en) 2014-10-28 2022-10-19 BCI Pharma Nucleoside kinase inhibitors
EA201890454A1 (ru) 2015-08-06 2018-07-31 Чимерикс, Инк. Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG10201912456RA (en) 2016-06-24 2020-02-27 Infinity Pharmaceuticals Inc Combination therapies
WO2019060692A1 (en) 2017-09-21 2019-03-28 Chimerix, Inc. MORPHIC FORMS OF 4-AMINO-7- (3,4-DIHYDROXY-5- (HYDROXYMETHYL) -ETRAHYDROFURAN-2-YL) -2-METHYL-7H-PYRROLO [2,3-D] PYRIMIDINE-5-CARBOXAMIDE AND THEIR USES
PE20221034A1 (es) 2019-08-08 2022-06-17 B C I Pharma Derivados de quinolina como inhibidores de proteina quinasa
CN115151550B (zh) * 2019-12-23 2024-11-22 桑福德·伯纳姆·普雷比医学发现研究所 外核苷酸焦磷酸酶/磷酸二酯酶1(enpp1)调节剂及其用途
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
CA3171648A1 (en) 2020-02-18 2021-08-26 Gilead Sciences, Inc. Antiviral compounds
AU2022256476B2 (en) 2021-04-16 2025-06-05 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
KR102639275B1 (ko) * 2021-06-08 2024-02-21 퓨쳐메디신 주식회사 다중 표적 인산화효소 저해 활성을 갖는 뉴클레오사이드 유도체 및 이를 포함하는 암의 예방 및 치료용 약학적 조성물
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4455420A (en) * 1983-01-13 1984-06-19 Hoffmann-La Roche Inc. 4-Amino-7-(5-deoxy-beta-D-ribofuranosyl)-5-iodo-7H-pyrrolo[2,3-d] pyrimidine
DE3712735A1 (de) * 1987-04-15 1988-11-10 Boehringer Mannheim Gmbh Neue pyrazolo(3,4-d)pyrimidine, verfahren zu ihrer herstellung und verwendung als arzneimittel
AU665184B2 (en) * 1991-01-23 1995-12-21 Gensia, Inc. Adenosine kinase inhibitors
FI933303A7 (fi) * 1991-01-23 1993-08-31 Gensia Inc Adenosiinikinaasi-inhibiittoreita
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
WO1994018215A1 (en) * 1993-02-03 1994-08-18 Gensia, Inc. Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
US6143749A (en) * 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds

Also Published As

Publication number Publication date
EP0832091A1 (en) 1998-04-01
CA2220642A1 (en) 1996-12-19
PL323904A1 (en) 1998-04-27
BR9609013A (pt) 1999-12-14
HUP9802193A3 (en) 1999-10-28
AP9701165A0 (en) 1998-01-31
IS4621A (is) 1997-11-26
ATE257841T1 (de) 2004-01-15
IL122335A0 (en) 1998-04-05
US5674998A (en) 1997-10-07
MX9709859A (es) 1998-08-30
TR199701539T1 (xx) 1998-04-21
AU6178396A (en) 1996-12-30
HUP9802193A2 (hu) 1999-05-28
JPH11507387A (ja) 1999-06-29
NO975585L (no) 1998-02-05
DE69631330D1 (de) 2004-02-19
OA10639A (en) 2002-09-17
NO975585D0 (no) 1997-12-03
CN1190401A (zh) 1998-08-12
EA199800009A1 (ru) 1998-06-25
DE69631330T2 (de) 2004-10-28
WO1996040705A1 (en) 1996-12-19
SK166097A3 (en) 1999-06-11
KR19990022740A (ko) 1999-03-25
EP0832091B1 (en) 2004-01-14
CZ392797A3 (cs) 1999-04-14

Similar Documents

Publication Publication Date Title
BG102163A (en) Inhibitors of adenosinekinase modified in c-4'position
MY102025A (en) Improvements in or relating to novel difluoro antiviral agents
MY102693A (en) Antiviral nucleosides
CA2215190A1 (en) Aryl-ester phosphoramidate derivatives of nucleosides
WO1996013512A3 (en) L-ribofuranosyl nucleosides
EP0526543A4 (en) Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents
DE69634779D1 (de) Wasserlösliche adenosin kinase inhibitoren
CA2167361A1 (en) 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
CA2033044A1 (en) 6-substituted purine carbocyclic nucleosides
DE69633860D1 (en) Oral aktive adenosinkinase-inhibitoren
EP2011499A3 (en) Pyrrolo[2,3d]Pyrimidine compositions and their use
AP2000001947A0 (en) Novel crystalline forms of an antiviral benzidazole compound.
CA2054870A1 (en) Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives
CA2151826A1 (en) Pharmaceutical compositions for prevention and treatment of cancerous diseases and process for their preparation
SG26364G (en) 2', 3'-dideoxy-3'-fluorothymidine and related compounds for the treatment of adenovirus infections
EP0334361A3 (en) Novel acetylenic, cyano and allenic aristeromycin/adenosine derivatives
IE893080L (en) Novel 2'-halomethylidene,2'-ethenylidene and¹2'-ethynyl adenosine derivatives
IE893991L (en) 2',3'-dideoxypurine nucleoside/purine nucleoside¹phosphorylase inhibitor combination therapy and composition
WO1996013498A3 (en) L-erythrosyl nucleosides
GR3019379T3 (en) Anti-HIV Pyrimidine Nucleosides
IE892654L (en) Therapeutic nucleosides
EP0335770A3 (en) Novel fluorophosphonate nucleotide derivatives
AU8239891A (en) 5'-hydrogenphosphonates and 5'-methylphosphonates of sugar modified nucleosides, compositions and uses thereof
MX9702927A (es) L-piranosilnucleosidos.
GB9506644D0 (en) Preparation of nucleoside analogues